埃尔洛尼布相关的间歇性肺炎与成功的再给药
Songphol Tungjitviboonkun1, Naharuthai Bumrungratanayos1, Jedsadakorn Jitwimungsanon1
1Department of Medicine, Sirindhorn Hospital, Bangkok, Thailand.
概括
埃洛提尼布是治疗非小细胞肺癌 (NSCLC) 的关键治疗方法. 一种罕见但致命的副作用,间歇性肺病,可能发生,但这种情况表明成功的erlotinib重新注射是可能的.
科学领域:
- 在瘤学瘤学.
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 埃洛提尼布是治疗非小细胞肺癌 (NSCLC) 的首要治疗方法.
- 间歇性肺病 (ILD) 是一种罕见但可能致命的不良事件,与erlotinib治疗有关.
- 及时治疗对于管理erlotinib诱导的ILD至关重要.
研究的目的:
- 报告在发生间歇性肺炎后首次成功重新给药erlotinib的病例.
- 突出一个患有NSCLC的患者经历了erlotinib诱导的ILD的治疗和结果.
- 探索改变埃洛提尼布 (erlotinib) 管理实践的可能性.
主要方法:
- 一个64岁的泰国男性患有NSCLC的病例报告.
- 详细介绍患者的症状,实验室发现和成像 (胸部X射线,CT).
- 皮质类固醇治疗的文件,埃洛尼布的再给药和疾病评估.
主要成果:
- 患者在初始埃洛提尼布治疗后发展出间歇性肺炎.
- 三周后,埃尔洛提尼布成功地重新注射,并没有出现不良事件的复发.
- 两个月后的疾病评估显示,根据RECIST v1.1标准,疾病稳定.
结论:
- 埃洛提尼布诱导的间歇性肺炎的机制可能是多样化的,并不总是与药物直接相关的.
- 在某些特定情况下,成功地重新注射埃洛提尼布是可行的.
- 这一案例可能会为未来的临床实践提供信息,以便在ILD后重新挑战erlotinib.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
相关概念视频
Pulmonary Tuberculosis V
202
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
202
Pneumothorax-II
205
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
205
Pleural Effusion II: Symptoms and Management
213
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
213
